Get Novoeight Counsel The Switch. Novoeight Counsel The Switch

NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII.

The molecule consists of a heavy chain of 87 kDa including a 21 amino acid residue truncated B-domain and a light chain of 79 kDa.

NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII.

Unlike , Afstyla is a single-chain recombinant FVIII with a truncated B-domain that allows covalent bonding of the light and heavy chains. This modification increases its affinity for VWF, which stabilizes and protects it from degradation.

NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII.

NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII.

NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII.

Source: Medicaid Data Warehouse, extracted on 3/6/2017 Proc CdProc DescrStatusJ7180INJECTION, FACTOR XIII (ANTIHEMOPHILIC FACTOR, HUMAN), 1 I.U.ActiveJ7181INJECTION, FACTOR XIII A–SUBUNIT, (RECOMBINANT), PER IUActiveJ7182INJECTION, FACTOR VIII, (ANTIHEMOPHILIC FACTOR, RECOMBINANT), (NOVOEIGHT), PER IUActive22 more rows • Mar 6, 2017

The molecule consists of a heavy chain of 87 kDa including a 21 amino acid residue truncated B-domain and a light chain of 79 kDa.

The molecule consists of a heavy chain of 87 kDa including a 21 amino acid residue truncated B-domain and a light chain of 79 kDa.

Difference between NovoSeven and NovoEight Even though both treatments are plasma-derived and recombinant analogues of blood clotting factors, NovoSeven is developed as a congenital FVIIa analogue for hemophilia A and B patients while NovoEight (turoctocog alfa) is for congenital FVIII deficiency.

The molecule consists of a heavy chain of 87 kDa including a 21 amino acid residue truncated B-domain and a light chain of 79 kDa.

NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII.

NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII.

Coding Table Information CodeDescriptor Generic NameReason for ExclusionJ1815INJECTION, , PER 5 UNITSAcceptable Evidentiary Criteria AvailableJ1817INSULIN FOR ADMINISTRATION THROUGH DME (I.E., PUMP) PER 50 UNITSAcceptable Evidentiary Criteria Available38 more rows

NovoEight is a medicine used to treat and prevent bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of factor VIII.

Unlike , Afstyla is a single-chain recombinant FVIII with a truncated B-domain that allows covalent bonding of the light and heavy chains. This modification increases its affinity for VWF, which stabilizes and protects it from degradation.

Unlike , Afstyla is a single-chain recombinant FVIII with a truncated B-domain that allows covalent bonding of the light and heavy chains. This modification increases its affinity for VWF, which stabilizes and protects it from degradation.

Unlike , Afstyla is a single-chain recombinant FVIII with a truncated B-domain that allows covalent bonding of the light and heavy chains. This modification increases its affinity for VWF, which stabilizes and protects it from degradation.

Source: Medicaid Data Warehouse, extracted on 3/6/2017 Proc CdProc DescrStatusJ7180INJECTION, FACTOR XIII (ANTIHEMOPHILIC FACTOR, HUMAN), 1 I.U.ActiveJ7181INJECTION, FACTOR XIII A–SUBUNIT, (RECOMBINANT), PER IUActiveJ7182INJECTION, FACTOR VIII, (ANTIHEMOPHILIC FACTOR, RECOMBINANT), (NOVOEIGHT), PER IUActive22 more rows • Mar 6, 2017

Mechanism of action NovoEight contains turoctocog alfa, a human coagulation factor VIII (rDNA), with a truncated B- domain. This glycoprotein has the same structure as human factor VIII when activated, and post- translational modifications that are similar to those of the plasma-derived molecule.

Source: Medicaid Data Warehouse, extracted on 3/6/2017 Proc CdProc DescrStatusJ7180INJECTION, FACTOR XIII (ANTIHEMOPHILIC FACTOR, HUMAN), 1 I.U.ActiveJ7181INJECTION, FACTOR XIII A–SUBUNIT, (RECOMBINANT), PER IUActiveJ7182INJECTION, FACTOR VIII, (ANTIHEMOPHILIC FACTOR, RECOMBINANT), (NOVOEIGHT), PER IUActive22 more rows • Mar 6, 2017

Source: Medicaid Data Warehouse, extracted on 3/6/2017 Proc CdProc DescrStatusJ7180INJECTION, FACTOR XIII (ANTIHEMOPHILIC FACTOR, HUMAN), 1 I.U.ActiveJ7181INJECTION, FACTOR XIII A–SUBUNIT, (RECOMBINANT), PER IUActiveJ7182INJECTION, FACTOR VIII, (ANTIHEMOPHILIC FACTOR, RECOMBINANT), (NOVOEIGHT), PER IUActive22 more rows • Mar 6, 2017

Difference between NovoSeven and NovoEight Even though both treatments are plasma-derived and recombinant analogues of blood clotting factors, NovoSeven is developed as a congenital FVIIa analogue for hemophilia A and B patients while NovoEight (turoctocog alfa) is for congenital FVIII deficiency.

Difference between NovoSeven and NovoEight Even though both treatments are plasma-derived and recombinant analogues of blood clotting factors, NovoSeven is developed as a congenital FVIIa analogue for hemophilia A and B patients while NovoEight (turoctocog alfa) is for congenital FVIII deficiency.

Development timeline for Novoeight DateArticleOct 16, 2013Approval NovoEight (turoctocog alfa) Receives Approval from the FDA

Difference between NovoSeven and NovoEight Even though both treatments are plasma-derived and recombinant analogues of blood clotting factors, NovoSeven is developed as a congenital FVIIa analogue for hemophilia A and B patients while NovoEight (turoctocog alfa) is for congenital FVIII deficiency.

Coding Table Information CodeDescriptor Generic NameReason for ExclusionJ1815INJECTION, , PER 5 UNITSAcceptable Evidentiary Criteria AvailableJ1817INSULIN FOR ADMINISTRATION THROUGH DME (I.E., PUMP) PER 50 UNITSAcceptable Evidentiary Criteria Available38 more rows

Coding Table Information CodeDescriptor Generic NameReason for ExclusionJ1815INJECTION, , PER 5 UNITSAcceptable Evidentiary Criteria AvailableJ1817INSULIN FOR ADMINISTRATION THROUGH DME (I.E., PUMP) PER 50 UNITSAcceptable Evidentiary Criteria Available38 more rows

HCPCS code J7182 for Injection, factor VIII, (antihemophilic factor, recombinant), (Novoeight), per IU as maintained by CMS falls under Clotting Factors .

Mechanism of action NovoEight contains turoctocog alfa, a human coagulation factor VIII (rDNA), with a truncated B- domain. This glycoprotein has the same structure as human factor VIII when activated, and post- translational modifications that are similar to those of the plasma-derived molecule.

Coding Table Information CodeDescriptor Generic NameReason for ExclusionJ1815INJECTION, , PER 5 UNITSAcceptable Evidentiary Criteria AvailableJ1817INSULIN FOR ADMINISTRATION THROUGH DME (I.E., PUMP) PER 50 UNITSAcceptable Evidentiary Criteria Available38 more rows

Mechanism of action NovoEight contains turoctocog alfa, a human coagulation factor VIII (rDNA), with a truncated B- domain. This glycoprotein has the same structure as human factor VIII when activated, and post- translational modifications that are similar to those of the plasma-derived molecule.

This medication is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.

Development timeline for Novoeight DateArticleOct 16, 2013Approval NovoEight (turoctocog alfa) Receives Approval from the FDA

Mechanism of action NovoEight contains turoctocog alfa, a human coagulation factor VIII (rDNA), with a truncated B- domain. This glycoprotein has the same structure as human factor VIII when activated, and post- translational modifications that are similar to those of the plasma-derived molecule.

Development timeline for Novoeight DateArticleOct 16, 2013Approval NovoEight (turoctocog alfa) Receives Approval from the FDA

HCPCS code J7182 for Injection, factor VIII, (antihemophilic factor, recombinant), (Novoeight), per IU as maintained by CMS falls under Clotting Factors .

Authorisation details Product detailsAgency product numberEMEA/H/C/002719Active substanceturoctocog alfaInternational non-proprietary name (INN) or common nameturoctocog alfaTherapeutic area (MeSH)Hemophilia A2 more rows

Development timeline for Novoeight DateArticleOct 16, 2013Approval NovoEight (turoctocog alfa) Receives Approval from the FDA

HCPCS code J7182 for Injection, factor VIII, (antihemophilic factor, recombinant), (Novoeight), per IU as maintained by CMS falls under Clotting Factors .

This medication is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.

HCPCS code J7182 for Injection, factor VIII, (antihemophilic factor, recombinant), (Novoeight), per IU as maintained by CMS falls under Clotting Factors .

This medication is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.

Authorisation details Product detailsAgency product numberEMEA/H/C/002719Active substanceturoctocog alfaInternational non-proprietary name (INN) or common nameturoctocog alfaTherapeutic area (MeSH)Hemophilia A2 more rows

This medication is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.

Authorisation details Product detailsAgency product numberEMEA/H/C/002719Active substanceturoctocog alfaInternational non-proprietary name (INN) or common nameturoctocog alfaTherapeutic area (MeSH)Hemophilia A2 more rows

Authorisation details Product detailsAgency product numberEMEA/H/C/002719Active substanceturoctocog alfaInternational non-proprietary name (INN) or common nameturoctocog alfaTherapeutic area (MeSH)Hemophilia A2 more rows